Have a personal or library account? Click to login
An Ensemble Fuzzy-MCDM Approach for Evaluation of Approved Monkeypox Vaccines Cover

An Ensemble Fuzzy-MCDM Approach for Evaluation of Approved Monkeypox Vaccines

Open Access
|Apr 2025

References

  1. Qu J, Zhang X, Liu K, et al (2024) A Comparative Evaluation of Three Diagnostic Assays for the Detection of Human Monkeypox. Viruses 16:. https://doi.org/10.3390/v16081286
  2. Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, et al (2024) Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. Nat Med. https://doi.org/10.1038/S41591-024-03130-3
  3. Watanabe Y, Kimura I, Hashimoto R, et al (2023) Virological characterization of the 2022 outbreak-causing monkey-pox virus using human keratinocytes and colon organoids. J Med Virol 95:e28827. https://doi.org/10.1002/JMV.28827
  4. McCarthy MW (2022) Therapeutic strategies to address monkeypox. Expert Rev Anti Infect Ther 20:1. https://doi.org/10.1080/14787210.2022.2113058
  5. 2022-24 Mpox (Monkeypox) Outbreak: Global Trends. https://worldhealthorg.shinyapps.io/mpx_global/#3_Global_situation_update. Accessed 23 Oct 2024
  6. Wilson ME, Hughes JM, McCollum AM, Damon IK (2014) Human Monkeypox. Clinical Infectious Diseases 58:260–267. https://doi.org/10.1093/CID/CIT703
  7. Shaheen N, Diab RA, Meshref M, et al (2022) Is there a need to be worried about the new monkeypox virus outbreak? A brief review on the monkeypox outbreak. Annals of Medicine and Surgery 81:104396. https://doi.org/10.1016/J.AMSU.2022.104396
  8. Garcia-Atutxa I, Mondragon-Teran P, Huerta-Saquero A, et al (2024) Advancements in monkeypox vaccines development: a critical review of emerging technologies. Front Immunol 15:1456060. https://doi.org/10.3389/FIMMU.2024.1456060
  9. JYNNEOS | FDA. https://www.fda.gov/vaccines-blood-biologics/jynneos. Accessed 6 Dec 2024
  10. MHRA-101097-PIP01-23-M01 (update) | MHRA. https://cms.mhra.gov.uk/pip/mhra-101097-pip01-23-m01-update. Accessed 6 Dec 2024
  11. Mpox.https://www.who.int/news-room/questions-and-answers/item/mpox. Accessed 9 Dec 2024
  12. Interim Clinical Considerations for Use of Vaccine for Mpox Prevention in the United States | Mpox | CDC. https://www.cdc.gov/mpox/hcp/vaccine-considerations/vaccination-overview.html. Accessed 9 Dec 2024
  13. Deputy NP, Deckert J, Chard AN, et al (2023) Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States. New England Journal of Medicine 388:2434–2443. https://doi.org/10.1056/NEJMOA2215201/SUPPL_FILE/NEJMOA2215201_DATA-SHARING.PDF
  14. Huber MN, Lim S (2023) Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023. Ann Emerg Med 82:520–522. https://doi.org/10.1016/J.ANNEMERGMED.2023.08.376
  15. Saguil A, Krebs L, Choe U (2023) Mpox: Rapid Evidence Review. Am Fam Physician 108:78–83
  16. Key Facts About Vaccines to Prevent Mpox Disease | FDA. https://www.fda.gov/vaccines-blood-biologics/vaccines/key-facts-about-vaccines-prevent-mpox-disease. Accessed 6 Dec 2024
  17. Rana J, Patel SK, Agrawal A, et al (2023) Mpox vaccination in global perspective: priorities and challenges. Annals of Medicine & Surgery 85:2243–2246. https://doi.org/10.1097/MS9.0000000000000550
  18. Kennedy JS, Greenberg RN (2009) IMVAMUNE®: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 8:13–24. https://doi.org/10.1586/14760584.8.1.13
  19. WHO adds LC16m8 mpox vaccine to Emergency Use Listing. https://www.who.int/news/item/19-11-2024-who-adds-lc16m8-mpox-vaccine-to-emergency-use-listing. Accessed 26 Nov 2024
  20. Yano R, Terada-Hirashima J, Uemura Y, et al (2023) Efficacy and Safety of the Smallpox Vaccine for Postexposure Prophylaxis in Monkeypox: Protocol for an Open-Labeled, Single-Armed Study. JMIR Res Protoc 12:e46955. https://doi.org/10.2196/46955
  21. Raju SK, Varadarajan GK, Alharbi AH, et al (2024) Estimating best nanomaterial for energy harvesting through reinforcement learning DQN coupled with fuzzy PROMETHEE under road-based conditions. Scientific Reports 2024 14:1 14:1–23. https://doi.org/10.1038/s41598-024-72194-5
  22. Mela K, Tiainen T, Heinisuo M (2012) Comparative study of multiple criteria decision making methods for building design. Advanced Engineering Informatics 26:716–726. https://doi.org/10.1016/J.AEI.2012.03.001
  23. Alsalem MA, Zaidan AA, Zaidan BB, et al (2018) Systematic Review of an Automated Multiclass Detection and Classification System for Acute Leukaemia in Terms of Evaluation and Benchmarking, Open Challenges, Issues and Methodological Aspects. J Med Syst 42:. https://doi.org/10.1007/S10916-018-1064-9
  24. Mareschal B (2005) Chapter 5: PROMETHEE methods Outranking & Decision open journal View project PROMETHEE MCDA methods View project
  25. Brans JP, de Smet Y (2016) PROMETHEE methods. International Series in Operations Research and Management Science 233:187–219. https://doi.org/10.1007/978-1-4939-3094-4_6
  26. Elevli B (2014) Logistics freight center locations decision by using Fuzzy-PROMETHEE. Vilnius Gediminas Technical University 29:412–418. https://doi.org/10.3846/16484142.2014.983966
  27. Wang W, Wang Y, Chen Y, et al (2024) Analyzing the barriers to resilience supply chain adoption in the food industry using hybrid interval-valued fermatean fuzzy PROMETHEE-II model. J Ind Inf Integr 40:100614. https://doi.org/10.1016/J.JII.2024.100614
  28. Uzun B, Usanase N, Ozsahin DU, Ozsahin I (2024) The Application of the Multi-Criteria Decision-Making Model in the Risk Assessment of Cervical Cancer Complications. In: 2024 Advances in Science and Engineering Technology International Conferences (ASET). IEEE, pp 1–5
  29. Usanase N, Uzun B, Ozsahin I, Ozsahin DU (2024) Optimizing Melanoma Therapy Decision-Making with a Multi-criteria Analytical Approach. 63–72. https://doi.org/10.1007/978-3-031-76283-3_11
  30. Usanase N, Uzun B, Ozsahin I, Ozsahin DU (2022) The preference ranking of gold nanoparticle synthesis methods using a multi-criteria decision-making model. IET Conference Proceedings 2022:314–320. https://doi.org/10.1049/ICP.2022.2481
  31. Hwang C-L, Yoon K (1981) Multiple Attribute Decision Making. 186:. https://doi.org/10.1007/978-3-642-48318-9
  32. JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Non-replicating). https://jynneos.com/. Accessed 17 Oct 2024
  33. Jarrell L, Perryman K (2023) Mpox (monkeypox): Diagnosis, prevention, and management in adults. Nurse Practitioner 48:13–20. https://doi.org/10.1097/01.NPR.0000000000000025
  34. WHO prequalifies the first vaccine against mpox. https://www.who.int/news/item/13-09-2024-who-prequalifiesthe-first-vaccine-against-mpox. Accessed 18 Oct 2024
  35. Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions | Emergent BioSolutions Inc. https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-bio-solutions-acam2000r-smallpox-and-mpox-vaccinia. Accessed 17 Oct 2024
  36. Hatch GJ, Graham VA, Bewley KR, et al (2013) Assessment of the Protective Effect of Imvamune and Acam2000 Vaccines against Aerosolized Monkeypox Virus in Cynomolgus Macaques. J Virol 87:7805–7815. https://doi.org/10.1128/JVI.03481-12/ASSET/544DE6DB-86D6-4298-B99E-14A907EFB75C/ASSETS/GRAPHIC/ZJV9990978360007.JPEG
  37. Kennedy JS, Gurwith M, Dekker CL, et al (2011) Safety and Immunogenicity of LC16m8, an Attenuated Smallpox Vaccine in Vaccinia-Naive Adults. J Infect Dis 204:1395. https://doi.org/10.1093/INFDIS/JIR527
  38. Saito T, Fujii T, Kanatani Y, et al (2009) Clinical and Immunological Response to Attenuated Tissue-Cultured Smallpox Vaccine LC16m8. JAMA 301:1025–1033. https://doi.org/10.1001/JAMA.2009.289
  39. 3RECOMMENDATION FOR AN EMERGENCY USE LISTING OF “Freeze-dried Smallpox Vaccine Prepared in Cell Culture LC16 “KMB” (LC16m8 vaccine) Submitted by KM Biologics, Japan
  40. Saadh MJ, Ghadimkhani T, Soltani N, et al (2023) Progress and prospects on vaccine development against monkeypox infection. Microb Pathog 180:106156. https://doi.org/10.1016/J.MICPATH.2023.106156
  41. Lambert de Rouvroit A, Heegaard ED (2016) Total costs associated with replicating and non-replicating smallpox vaccines. Global Security: Health, Science and Policy 1:3–9. https://doi.org/10.1080/23793406.2016.1171944
  42. Ozsahin I, Usanase N, Uzun B, et al (2024) A mathematical resolution in selecting suitable magnetic field-based breast cancer imaging modality: a comparative study on seven diagnostic techniques. Artificial Intelligence and Image Processing in Medical Imaging 173–194. https://doi.org/10.1016/B978-0-323-95462-4.00007-8
  43. Abdullah L, Chan W, Afshari A Application of PROMETHEE method for green supplier selection: a comparative result based on preference functions. https://doi.org/10.1007/s40092-018-0289-z
  44. Vaccines and immunization: Vaccine safety. https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-vaccine-safety. Accessed 28 Nov 2024
  45. Okumura N, Morino E, Nomoto H, et al (2024) Safety and Effectiveness of LC16m8 for Pre-Exposure Prophylaxis against mpox in a High-Risk Population: An Open-Label Randomized Trial. medRxiv 2024.06.06.24308551. https://doi.org/10.1101/2024.06.06.24308551
  46. Kuehn BM (2022) Newer Poxvirus Vaccine Is Recommended. JAMA 328:123–123. https://doi.org/10.1001/JAMA.2022.11221
  47. Payne AB, Ray LC, Kugeler KJ, et al (2022) Incidence of Monkeypox Among Unvaccinated Persons Compared with Persons Receiving ≥1 JYNNEOS Vaccine Dose — 32 U.S. Jurisdictions, July 31–September 3, 2022. MMWR Morb Mortal Wkly Rep 71:1278–1282. https://doi.org/10.15585/MMWR.MM7140E3
  48. Pischel L, Martini BA, Yu N, et al (2024) Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis. Vaccine 42:126053. https://doi.org/10.1016/J.VACCINE.2024.06.021
  49. Abdelaal A, Reda A, Lashin BI, et al (2022) Preventing the Next Pandemic: Is Live Vaccine Efficacious against Monkeypox, or Is There a Need for Killed Virus and mRNA Vaccines? Vaccines 2022, Vol 10, Page 1419 10:1419. https://doi.org/10.3390/VACCINES10091419
Language: English
Page range: 154 - 164
Published on: Apr 17, 2025
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2025 Natacha Usanase, Declan Ikechukwu Emegano, Berna Uzun, Dilber Uzun Ozsahin, Ilker Ozsahin, published by European Biotechnology Thematic Network Association
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.